Since the immunohistochemical assessment of protein expression levels for prognostic and/or predictive purposes is already in clinical use in other tumor types (e.g. hormone receptors and proliferative activity in breast cancer), the analysis of rpS6 and p-rpS6 for prognostication of RCC patients seems feasible. Here, NR4A1 is linked to neoplasm.